BUPROPION-SR FOR SMOKING CESSATION IN EARLY RECOVERY FROM ALCOHOL DEPENDENCE

安非他酮缓释剂用于戒烟，帮助从酒精依赖中早期恢复

• 批准号: 7376525
• 负责人: MAHER A. KARAM-HAGE
• 金额: $ 1.23万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376525
• 关键词: alcohols; bupropion; smoking; smoking cessation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine how effective the medication, bupropion-SR, is for treating smoking cessation during early recovery from alcohol dependence. Bupropion-SR is a medication that has been approved by the United States Food and Drug Administration (FDA) for the treatment of smoking cessation. We expect that this medication will be useful in initiating smoking cessation, and maintaining abstinence from smoking, among patients in early recovery from alcohol dependence. A vast majority of patients treated for alcohol dependence also smoke cigarettes. Cigarette smoking is associated with serious, preventative health risks, and premature death. Studies have shown that those who are treated for alcohol dependence, and who quit smoking, are also less likely to relapse to alcohol use. Men and women, 18 years of age or older, who meet study criteria for alcohol and nicotine dependence, and who have been abstinent from alcohol for 6 weeks to 6 months, may be eligible to participate. They must state a desire to quit smoking and identify a "quit date." In addition, individuals must be able to identify a family member or friend whom we can contact to ask about their alcohol and tobacco use. Individuals cannot participate if they have any history of seizure disorder, severe head trauma, brain tumor, or stroke. Likewise, they cannot participate if they take any medications that may make it inadvisable to take bupropion-SR. Individuals who have a medical or psychiatric illness, or who are currently dependent on, or heavily use other drugs are ineligible. Women who are nursing, pregnant, or likely to become pregnant during this study are also ineligible. A total of 80 subjects will be recruited for this study from Chelsea Arbor Treatment Center. We will admit people who qualify for this study in the order that they complete the initial assessments. By joining this study, you may quit smoking, and, therefore, your overall health may improve. Most importantly, you could possibly improve your chances of sustained sobriety. You will receive regular visits with a therapist, psychiatrist, nurse practitioner, and/or registered nurse to help you with your abstinence from alcohol and cigarettes. Approximately one-half of study participants will be given bupropion-SR, at no cost. Research indicates that you have a greater chance of successfully quitting smoking if you participate in smoking cessation counseling than if you try to quit on your own. Those who are receiving active medication in addition to smoking cessation counseling may have even greater success in quitting.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。本研究的目的是确定药物安非他酮 SR 在酒精依赖早期恢复过程中治疗戒烟的效果如何。安非他酮 SR 是一种已获得美国食品和药物管理局 (FDA) 批准用于治疗戒烟的药物。我们预计这种药物将有助于在酒精依赖早期恢复的患者中开始戒烟并保持戒烟。绝大多数接受酒精依赖治疗的患者也吸烟。吸烟与严重的预防性健康风险和过早死亡有关。研究表明，那些接受酒精依赖治疗并戒烟的人也不太可能再次酗酒。年满 18 岁、符合酒精和尼古丁依赖研究标准并且已戒酒 6 周至 6 个月的男性和女性可能有资格参加。他们必须表达戒烟的愿望并确定“戒烟日期”。此外，个人必须能够确定我们可以联系的家庭成员或朋友，询问他们的饮酒和吸烟情况。如果个人有任何癫痫病、严重头部外伤、脑肿瘤或中风病史，则不能参加。同样，如果他们服用任何可能不建议服用安非他酮缓释剂的药物，他们也不能参加。患有医学或精神疾病的个人，或者目前依赖或大量使用其他药物的个人不符合资格。在本研究期间正在哺乳、怀孕或可能怀孕的女性也不符合资格。这项研究将从切尔西阿伯治疗中心招募总共 80 名受试者。我们将按照完成初步评估的顺序录取符合本研究资格的人员。通过参加这项研究，您可能会戒烟，因此您的整体健康状况可能会得到改善。最重要的是，您可以提高持续清醒的机会。您将接受治疗师、精神科医生、执业护士和/或注册护士的定期拜访，以帮助您戒烟戒酒。大约一半的研究参与者将免费获得安非他酮缓释剂。研究表明，参加戒烟咨询比尝试自行戒烟成功戒烟的机会更大。那些除了戒烟咨询之外还接受积极药物治疗的人可能会取得更大的戒烟成功率。